ABPI response to Innovative Medicines Fund announcement

The Government has today launched the Innovative Medicines Fund, to fast track the most promising medicines in the NHS. 

The Innovative Medicines Fund provides an important opportunity to support NHS patients in getting early access to promising new treatments, including those with rare diseases.  Richard Torbett, Chief Executive, ABPI

In response to the news, ABPI Chief Executive Richard Torbett said: 

“The Innovative Medicines Fund provides an important opportunity to support NHS patients in getting early access to promising new treatments, including those with rare diseases. 

“If patients are to see maximum benefit from the Fund, industry, the NHS and NICE will need to work closely together to ensure there are no unnecessary barriers for medicines to enter it.  We look forward to seeing more detail on how the Fund will operate in practice.”

TAGS
  • Early Access to Medicines Scheme (EAMS)

Related news

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.